CFAP92

Across TCGA pan-cancer cohorts, CFAP92 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CFAP92 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CFAP92 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CFAP92 expression acts as an unfavorable survival marker.

LUAD, SKCM, and CESC are the cancer types where CFAP92 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.454	0.793	.001	21	view →
SKCM	OS	Median	II,III,IV	0.412	0.750	<.001	12	view →
CESC	DFS	Median	III,IV	0.240	0.726	.015	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.181	0.708	.002	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CFAP92–LUAD (DFS)

Open the LUAD breakdown →